In hormone-sensitive prostate cancer, an alternative dosing of docetaxel plus Nubeqa and ADT was associated with improvements in side effect rates.

A powerful new drug combination—niraparib added to standard prostate cancer therapy—has been shown to significantly delay ...

A new drug combination cuts the risk of death in people with advanced prostate cancer by 40% over eight years, according to ...

Breast cancer affects many women globally. While most cases are random, some stem from inherited genes like BRCA1 and BRCA2.

A targeted drug combination delays advanced prostate cancer in men with specific DNA repair gene mutations. A large international study led by researchers at UCL has found that a new combination of dr ...

(UroToday.com) The 2025 ESMO annual meeting featured a metastatic castration-resistant prostate cancer (mCRPC) session and a ...

(UroToday.com) The 2025 European Society of Medical Oncology (ESMO) Annual Congress held in Berlin, Germany between September 17 th and 21 st was host to the session Mini oral session: GU tumours, ...

Men with genes that increase the risk of prostate cancer should have annual checks from the age of 40, research has shown.

Men with BRCA1 and BRCA2 gene mutations should be given annual prostate cancer screening checks, leading scientists have said ...

Cancer experts warn these men should have prostate screenings every year - BRCA gene mutations are linked to a higher chance ...

With the backing of Rishi Sunak, Prostate Cancer UK published a report to the national screening committee back in 2022 in ...

A new international study led by researchers at University College London (UCL) has found that a new drug combination could ...